BioMarin Hid 'Revolutionary' Drug's Troubles, Investor Says

By Katryna Perera (February 24, 2023, 10:15 PM EST) -- California-based BioMarin Pharmaceutical Inc. and two of its executives face an investor suit accusing them of failing to disclose troubles facing its "revolutionary" Hemophilia A gene therapy Valrox during its testing and approval process, while at the same time selling off "uncharacteristically" large amounts of BioMarin stock at artificially inflated prices....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!